Fund detail
Viking Global Investors (Halvorsen)
hedge-fund, active
Quarters
52
2021-06-30
$32.98B
Positions
88
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
Price is the latest implied close from the selected quarter's 13F (value ÷ shares). Est. Cost is a running average that assumes each quarter's trades cleared near the midpoint of consecutive 13F closes (or yfinance VWAP when available). Most accurate for slow accumulators, least accurate for activists who build positions in a few days.
| # | Issuer | Value ↓ | Weight | Shares | Share Δ | Share Δ % | Prev Weight | First Held | Price | Est. Cost | Unrealized % | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BRIDGEBIO PHARMA INC BBIO | $1.62B | 4.92% | 26,620,991 | +0 | +0.00% | 4.88% | 2019-06-30 | $61 | ~$27 | +126.03% | |
| 2 | ADAPTIVE BIOTECHNOLOGIES COR ADPT | $1.23B | 3.72% | 29,993,708 | +0 | +0.00% | 3.60% | 2019-06-30 | $41 | ~$48 | -15.40% | |
| 3 | API GROUP CORP APG | $696.3M | 2.11% | 33,333,333 | +0 | +0.00% | 2.05% | 2020-06-30 | $21 | ~$12 | +71.93% | |
| 4 | INHIBRX INC INBXUSD | $146.0M | 0.44% | 5,305,866 | +0 | +0.00% | 0.32% | 2020-09-30 | $28 | ~$18 | +52.89% | |
| 5 | ZENTALIS PHARMACEUTICALS INC ZNTL | $127.6M | 0.39% | 2,399,284 | +0 | +0.00% | 0.31% | 2020-06-30 | $53 | ~$48 | +10.79% | |
| 6 | 4D MOLECULAR THERAPEUTICS IN FDMT | $94.8M | 0.29% | 3,937,914 | +0 | +0.00% | 0.51% | 2020-12-31 | $24 | ~$41 | -41.91% |